Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $415.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 24.2% to $415.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, down 22.64% year-over-year, with the annual reading at $415.9 million for FY2025, 24.2% down from the prior year.
  • Liabilities and Shareholders Equity hit $415.9 million in Q4 2025 for Allogene Therapeutics, down from $439.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q1 2021 to a low of $415.9 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $758.5 million across 5 years, with a median of $731.8 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 71.24% in 2021 and later dropped 27.25% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then decreased by 21.82% to $821.6 million in 2022, then dropped by 21.76% to $642.8 million in 2023, then decreased by 14.64% to $548.7 million in 2024, then decreased by 24.2% to $415.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ALLO at $415.9 million in Q4 2025, $439.8 million in Q3 2025, and $470.6 million in Q2 2025.